DB-2304 + Placebo for lupus erythematosus, cutaneous

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Oct 2024: Trial registered, NCT06625671
  2. 4 Oct 2024: Trial started, NCT06625671

The trials

NCT06625671: A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

State
Under way
Phase
Phase 1 and Phase 2
People
148 planned
Started
4 Oct 2024
Primary completion
30 Jun 2027
Arms
Dose Level 6, Dose Level 7, Dose Level 8
Results
None posted
  1. 3 Oct 2024: Trial registered
  2. 4 Oct 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.